seekingalpha.com
Professional Investor Explains His 2 Largest Healthcare Holdings
Jan. 22, 2014 12:48 PM ET
By Jake King
Sarepta Therapeutics (SRPT) had a tumultuous year, reaching an all-time high of $55.00 last October before tumbling to lows under $13.00 when the U.S. FDA suggested that the company would need to run a phase 3 trial of its lead drug cand…